Filtered By:
Specialty: Pharmaceuticals
Condition: Heart Attack
Education: Study
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 79 results found since Jan 2013.
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
RARITAN, NJ, May 25, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor (being developed in collaboration with Bristol Myers Squibb), have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients. The Librexia program is unrivaled as the most comprehensive FXIa clinical...
Source: Johnson and Johnson - May 25, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
ASA: Increased Odds of Stroke, MI With E-Cigarette Use
WEDNESDAY, Jan. 30, 2019 -- Electronic cigarette use is associated with increased odds of stroke, myocardial infarction, and angina or coronary heart disease, according to a study presented at the American Stroke Association International Stroke...
Source: Drugs.com - Pharma News - January 30, 2019 Category: Pharmaceuticals Source Type: news
Aspirin green light for brain bleed stroke patients, study finds
People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major clinical trial has found. Researchers say the findings are reassuring for the thousands of people who take the medicines to reduce their risk of heart attack and another common type of stroke caused by blood clots in the brain.
Source: World Pharma News - May 23, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Green Tea Consumption Improves Prognosis for Stroke, MI Survivors
THURSDAY, Feb. 4, 2021 -- For stroke and myocardial infarction (MI) survivors, green tea consumption is associated with improved prognosis, according to a study published online Feb. 4 in Stroke.
Masayuki Teramoto, M.D., from the Osaka University...
Source: Drugs.com - Pharma News - February 4, 2021 Category: Pharmaceuticals Source Type: news
Women With Migraine Have Higher Risk for Heart Attack, Hemorrhagic Stroke
TUESDAY, June 13, 2023 -- The risk for ischemic stroke in individuals with migraine is similar for men and women, while the risk for myocardial infarction (MI) and hemorrhagic stroke is only higher in women with migraine, according to a study...
Source: Drugs.com - Pharma News - June 13, 2023 Category: Pharmaceuticals Source Type: news
Social Isolation, Loneliness May Increase AMI, Stroke Risk
TUESDAY, March 27, 2018 -- Isolation and loneliness may be associated with increased risk of acute myocardial infarction (AMI) and stroke, according to a study published online March 27 in Heart.
Christian Hakulinen, Ph.D., from the University of...
Source: Drugs.com - Pharma News - March 27, 2018 Category: Pharmaceuticals Source Type: news
Rate of MI, Stroke Higher After Respiratory Infection
FRIDAY, March 30, 2018 -- The risk for myocardial infarction (MI) or stroke remains higher after laboratory-confirmed Streptococcus pneumoniae or influenza, according to a study published March 21 in the European Respiratory Journal.
Charlotte...
Source: Drugs.com - Pharma News - March 30, 2018 Category: Pharmaceuticals Source Type: news
Increased Risk of MI, Ischemic Stroke After COPD Exacerbation
TUESDAY, June 19, 2018 -- For adults with chronic obstructive pulmonary disease (COPD), acute exacerbations are associated with increased risk of myocardial infarction and ischemic stroke, according to a study published online May 3 in the Annals of...
Source: Drugs.com - Pharma News - June 19, 2018 Category: Pharmaceuticals Source Type: news
WTC-Related PTSD May Up Risk for Stroke, MI in Clean-Up Crew
THURSDAY, July 19, 2018 -- World Trade Center-related post-traumatic stress disorder (PTSD) is a risk factor for myocardial infarction (MI) and stroke among workers involved in cleaning up the debris, according to a study published in the June issue...
Source: Drugs.com - Pharma News - July 19, 2018 Category: Pharmaceuticals Source Type: news
Psychological Distress Linked to Increased Risk of MI, Stroke
THURSDAY, Sept. 6, 2018 -- Psychological distress is associated with myocardial infarction (MI) and stroke in men and women, according to a study published online Aug. 28 in Circulation: Cardiovascular Quality and Outcomes.
Caroline A. Jackson,...
Source: Drugs.com - Pharma News - September 6, 2018 Category: Pharmaceuticals Source Type: news
AMI, Stroke Risk Elevated for Women With Preeclampsia Within 20 Years
FRIDAY, Feb. 3, 2023 -- Women with a history of preeclampsia have a significantly increased risk for acute myocardial infarction (AMI) and ischemic stroke within and after 10 years of delivery, according to a study published online Jan. 26 in the...
Source: Drugs.com - Pharma News - February 3, 2023 Category: Pharmaceuticals Source Type: news
Risk for MI, Ischemic Stroke Increased for Younger Adults With Mental Disorders
TUESDAY, May 9, 2023 -- Younger adults with mental disorders have an increased risk for myocardial infarction (MI) and ischemic stroke (IS), according to a study published online April 28 in the European Journal of Preventive Cardiology.
Chan Soon...
Source: Drugs.com - Pharma News - May 9, 2023 Category: Pharmaceuticals Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
